ClinicalTrials.gg
CompletedNCT02608450Updated Nov 20, 2020Results posted

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)

A Phase 3 interventional study of CB-03-01 cream, 1% and Vehicle cream in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 54 sites in 3 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
2nd of 19
708 · median 50
Started
2016
with 2 others
Phase 3
5 of 19
2 open now
Registered
3rd of 19
by date
Lead sponsor
4 of 19
Cassiopea SpA

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 3rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • clascoterone
  • anti-androgen
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is male or non-pregnant female, 9 years of age or older. Females must be , surgically sterile, or using highly effective methods. Women of must have a negative urine pregnancy test (UPT) at the Screening/Baseline Visit.
  2. Subject has provided written and verbal /assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing.
  3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4 (severe) [0 (clear) to 4 (severe) scale].
  4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones).
  5. Subject and parent/guardian (if applicable) are willing to comply with study instructions and return to the clinic for required visits.
  6. Subject has used the same type and brand of make-up, other facial products (exclusive of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
  3. Subject has greater than two (2) facial nodules.
  4. Subject has nodulocystic acne.
  5. Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  6. Subject is currently enrolled in an drug or device study.
  7. Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline).
  8. Subject has facial hair that could interfere with the study assessments in the opinion of the investigator.
  9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
  10. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
  11. Subject has known or previous allergic reaction to any of the active or inactive components of the test articles.
  12. Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.
  13. Subject has used any of the prohibited topical anti-acne treatments or procedures prior to the study unless appropriate is documented.
  14. Subject has used used any of the prohibited systemic anti-acne medications prior to the study unless appropriate washout period is documented.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
708 participants (actual)

Study arms

  • Experimental
    CB-03-01 cream

    CB-03-01 cream, 1% applied twice daily for 12 weeks

    Drug: CB-03-01 cream, 1%

  • Placebo comparator
    Vehicle cream

    Vehicle cream applied twice daily for 12 weeks

    Drug: Vehicle cream

Interventions

  • CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

    Also known as: cortexolone 17α-propionate, clascoterone (USAN, INN)

  • DrugVehicle cream

    Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

    Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

    Time frame: Week 12

  2. Change From Baseline in Non-inflammatory Lesion Counts

    Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Inflammatory Lesion Counts

    Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Total Lesion Counts

    Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Total Lesion Counts

    Percent change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts

    Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Inflammatory Lesion (IL) Counts

    Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

    Time frame: Baseline and Week 12

Other outcomes

  1. Local Site Reactions

    Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).

    Time frame: Baseline, Weeks 4, 8, and 12

07

Results

Posted Nov 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneCB-03-01 CreamVehicle Cream
Started353355
Completed287290
Not completed6665
Withdrew: Lost to follow-up3932
Withdrew: Withdrawal by subject2115
Withdrew: Adverse event36
Withdrew: Withdrawal by parent23
Withdrew: Lack of efficacy03
Withdrew: Noncompliance with study drug02
Withdrew: Physician decision01
Withdrew: Pregnancy01
Withdrew: Progressive disease10
Withdrew: Multiple reasons02

Outcome measures

PrimaryPercentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)
Percentage of participantsCB-03-01 CreamVehicle Cream
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)18.49.0
PrimaryChange From Baseline in Non-inflammatory Lesion Counts

Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · Non-inflammatory Lesions
Change From Baseline in Non-inflammatory Lesion Counts
Non-inflammatory LesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Non-inflammatory Lesion Counts-19.4 (-22.6 to -16.7)-13.0 (-15.7 to -10.3)
PrimaryChange From Baseline in Inflammatory Lesion Counts

Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · Inflammatory Lesions
Change From Baseline in Inflammatory Lesion Counts
Inflammatory LesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Inflammatory Lesion Counts-19.3 (-21.1 to -17.5)-15.5 (-17.3 to -13.6)
SecondaryChange From Baseline in Total Lesion Counts

Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · Total lesions
Change From Baseline in Total Lesion Counts
Total lesionsCB-03-01 CreamVehicle Cream
Change From Baseline in Total Lesion Counts-39.1 (-43.0 to -35.1)-28.8 (-32.6 to -24.9)
SecondaryPercent Change From Baseline in Total Lesion Counts

Percent change from Baseline in total lesions counts in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Total Lesion Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Total Lesion Counts-37.0 (-40.9 to -33.2)-28.4 (-32.3 to -24.6)
SecondaryPercent Change From Baseline in Non-inflammatory Lesion (NIL) Counts

Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts-30.6 (-35.6 to -25.7)-21.6 (-26.4 to -16.8)
SecondaryPercent Change From Baseline in Inflammatory Lesion (IL) Counts

Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Inflammatory Lesion (IL) Counts
percent changeCB-03-01 CreamVehicle Cream
Percent Change From Baseline in Inflammatory Lesion (IL) Counts-44.8 (-49.0 to -40.5)-36.5 (-40.8 to -32.2)
Other pre-specifiedLocal Site Reactions

Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).

Time frame:
Baseline, Weeks 4, 8, and 12

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.. Non-serious events are listed at a 0.6% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CB-03-01 Cream0/353 (0%)0/353 (0%)9/353 (2.5%)
Vehicle Cream0/355 (0%)1/355 (0.3%)18/355 (5.1%)
Most frequent serious events
Most frequent serious events
EventCB-03-01 CreamVehicle Cream
PneumoniaInfections and infestations0/3531/355
Most frequent other events
Most frequent other events
EventCB-03-01 CreamVehicle Cream
NasopharyngitisInfections and infestations6/35312/355
Application painGeneral disorders1/3533/355
Application site pruritusInjury, poisoning and procedural complications2/3533/355

Baseline characteristics

Number of participants is based on the Intent to treat dataset.

Age, Continuous
Age, Continuous(years)CB-03-01 CreamVehicle CreamTotal
Mean20.0 ± 6.719.9 ± 6.819.9 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)CB-03-01 CreamVehicle CreamTotal
Female221215436
Male132140272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CB-03-01 CreamVehicle CreamTotal
Hispanic or Latino9480174
Not Hispanic or Latino259275534
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CB-03-01 CreamVehicle CreamTotal
American Indian or Alaska Native011
Asian91019
Native Hawaiian or Other Pacific Islander202
Black or African American313869
White298297595
More than one race9716
Unknown or Not Reported426
Baseline IGA
Baseline IGA(Participants)CB-03-01 CreamVehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2- Mild000
3 - Moderate292291583
4 - Severe6164125
Baseline Acne Lesion Counts
Baseline Acne Lesion Counts(Lesions)CB-03-01 CreamVehicle CreamTotal
Non-inflammatory lesions59.1 ± 22.260.7 ± 22.159.9 ± 22.1
Inflammatory lesions42.4 ± 11.842.9 ± 12.342.7 ± 12.1
Total Lesion Count101.5 ± 25.1103.6 ± 26.1102.6 ± 25.6
08

Study locations

54 sites
  • Gary M. Petrus, MD PA
    Little Rock, Arkansas 72205, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Vitiligo & Pigmentation Institute of Southern California
    Los Angeles, California 90036, United States
  • San Diego Sports Medicine and Family Health Center
    San Diego, California 92120, United States
  • Rady Childrens Hospital, Pediatric and Adolescent Dermatology
    San Diego, California 92123, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Memorial Research Medical Clinic dba / Orange County Research Center
    Tustin, California 92780, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Site 0190
    Boca Raton, Florida 33434, United States
  • Study Protocol, Inc.
    Boynton Beach, Florida 33437, United States
  • Site 0196
    Miami, Florida 33125, United States
  • Site 0197
    Miami, Florida 33126, United States
  • Site 0198
    Miami, Florida 33135, United States
  • Site 0199
    Miami, Florida 33145, United States
  • Site 0191
    Miami, Florida 33172, United States
  • Site 0192
    Miami, Florida 33172, United States
  • Site 0195
    Miami, Florida 33176, United States
  • Tory Sullivan, M.D., P.A.
    North Miami Beach, Florida 33162, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • MOORE Clinical Research, Inc.
    Tampa, Florida 33609, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Site 0152
    Carmel, Indiana 46032, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • The Center for Dermatology, Cosmetic & Laser Surgery
    Mount Kisco, New York 10549, United States
  • DermResearch Center of New York, Inc.
    Stony Brook, New York 11790, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • The Pennsylvania State University and the Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Greenville Dermatology, LLC
    Greenville, South Carolina 29607, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Westlake Dermatology Clinical Research Center
    Austin, Texas 78746, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • J&S Studies, Inc.
    College Station, Texas 77845, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • Clinical Research Associates of Tidewater, Inc.
    Norfolk, Virginia 23507, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Site 9911
    Tbilisi, 0159, Georgia
  • Site 9913
    Tbilisi, 0179, Georgia
  • Site 9912
    Tbilisi, 0194, Georgia
  • Site 3802
    Dnipro, 49000, Ukraine
  • Site 3804
    Kharkiv, 31038, Ukraine
  • 3808
    Kharkiv, 61002, Ukraine
  • Site 3801
    Kyiv, 01601, Ukraine
  • 3807
    Lviv, 79014, Ukraine
  • Site 3803
    Ternopil', 46006, Ukraine
  • Site 3809
    Zaporizhzhya, 69063, Ukraine
09

References and documents

Publications

  • Piszczatoski CR, Powell J. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years. Clin Ther. 2021 Oct;43(10):1638-1644. doi: 10.1016/j.clinthera.2021.08.007. Epub 2021 Oct 2. PubMed 34607697 ↗
  • Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. PubMed 32320027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Apr 2018, 26 months.

Results were first posted in Nov 2020, 2 years 7 months after primary completion. A results delay was requested in Jun 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 26 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Nov 18, 2015
StartActual
Jan 21, 2016
Primary completionActual
Apr 11, 2018
CompletionActual
Apr 11, 2018
Results delay requested
Jun 7, 2019
Results first posted
Nov 20, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02608450
Lead sponsor
Cassiopea SpA
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Jan 21, 2016
Primary completion
Apr 11, 2018
Completion
Apr 11, 2018
Results posted
Nov 20, 2020
Last update
Nov 20, 2020

Study contacts

R&D Cassiopea
study director · Cassiopea S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion